Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SunRISe-1: TAR-200 and cetrelimab in high-risk BCG-unresponsive NMIBC
jRCT2071200086Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised trial of gemcitabine-releasing intravesical system and cetrelimab in non-muscle-invasive bladder cancer (NMIBC) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall complete clinical response rate (Cohorts 1, 2, 3) and Disease-free survival (Cohort 4). Started Jul 2021; status: recruiting.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2071200086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200086.